Multiple Sclerosis
Conditions
Brief summary
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system, beginning most often in subjects aged 20-40 years. In France, thanks to recent studies reported during general states of MS in 2006, the prevalence is estimated at 65.5 / 100,000 population (96.3 / 100,000 women and 41.9 / 100,000 men) and incidence at 7.91 per 100,000. In Lower Normandy, the incidence of MS is estimated to 4.45 / 100,000 inhabitants or 60 new cases per year. The primary objective of this pilot study is to assess the levels of glutamate and aspartate (excitotoxicity markers) and their repercussions on the clinical and radiological outcome in 40 patients experiencing an event demyelinating central nervous system.
Interventions
BIOLOGICALglutamate and aspartate
Sponsors
University Hospital, Caen
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Man or woman between 18 and 60 years old. * Patient with one or more type of inflammatory events of Central system suggestive of demyelinating disease (multiple sclerosis, neuromyelitis optical Devic extensive myelitis) * No treatment with corticosteroids for less than 1 month * Need for a lumbar puncture performed in the etiologic * Need a brain MRI performed within the etiologic * Patient who signed informed consent
Exclusion criteria
* Secondary progressive MS * Any cons-indication for lumbar puncture * Any contra-indication to MRI * Minor patient or patient major under guardianship
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| glutamate concentration (in nM) | baseline | comparison between MS patients and controls |
Outcome results
None listed